NCT04894474View on ClinicalTrials.gov

A Study to Test Whether BI 767551 Can Prevent COVID-19 in People Who Have Been Exposed to SARS-CoV-2

PHASE2/PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 17, 2021

Primary Completion Date

May 23, 2022

Study Completion Date

July 24, 2022

Conditions
COVID-19
Interventions
DRUG

BI 767551 intravenous

BI 767551 intravenous

DRUG

BI 767551 inhalation

BI 767551 inhalation

DRUG

Placebo intravenous

Placebo intravenous

DRUG

Placebo inhalation

Placebo inhalation

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT04894474 - A Study to Test Whether BI 767551 Can Prevent COVID-19 in People Who Have Been Exposed to SARS-CoV-2 | Biotech Hunter | Biotech Hunter